Implementation of the American Diabetes Association's Standards of Medical Care post-Medicare Part D

The case of statin utilization in the elderly with diabetes

Z. Kevin Lu, Minghui Li, Whitney D. Maxwell, Richard M. Schulz

Research output: Contribution to journalArticle

Abstract

Background: The American Diabetes Association's (ADA's) Standards of Medical Care in Diabetes for statin use have changed to be driven by risk status rather than low-density lipoprotein cholesterol level. Objectives: The objectives of this study were to 1) examine how statins were used by risk status in elderly diabetics for whom they are recommended by the ADA's Standards with high levels of evidence, and 2) identify potential predictors of statin non-use using data containing Medicare Part D information in understanding how to further align patient care with the ADA's Standards. Methods: This study was a pooled cross-sectional study of the Medicare Current Beneficiaries Survey from 2006 to 2010. Sampling weights were applied to generate national estimates. Weighted logistic regression was performed to identify potential predicators of statin non-use. Results: Between 2006 and 2010, 53.96%, 52.14%, 52.28%, 57.74%, and 59.81% of eligible diabetics used statins, respectively. About 70% of the patients with overt cardiovascular disease (CVD) took statins while only about 50% of those with CVD risk factors used statins in 2010. Compared to those with overt CVD, patients with CVD risk factors were less likely to take statins (OR: 0.56; 95% CI: 0.48-0.64). Other non-use predictors included: non-Hispanic Black, non-metropolitan areas, and comorbidities. Conclusions: Implementation of the ADA's statin recommendations increased over the study period. Statin use differed significantly by patients' risk status. Future ADA's Standards focusing on how to improve utilization of statins for individuals with different risk status, particularly those with CVD risk factors but without overt CVD, are warranted.

Original languageEnglish (US)
Pages (from-to)419-427
Number of pages9
JournalResearch in Social and Administrative Pharmacy
Volume12
Issue number3
DOIs
StatePublished - May 1 2016

Fingerprint

Medicare Part D
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Standard of Care
Medical problems
Health care
Cardiovascular Diseases
Medicare
LDL Cholesterol
Logistics
Comorbidity

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmaceutical Science

Cite this

Implementation of the American Diabetes Association's Standards of Medical Care post-Medicare Part D : The case of statin utilization in the elderly with diabetes. / Lu, Z. Kevin; Li, Minghui; Maxwell, Whitney D.; Schulz, Richard M.

In: Research in Social and Administrative Pharmacy, Vol. 12, No. 3, 01.05.2016, p. 419-427.

Research output: Contribution to journalArticle

@article{09c146426afd4d7694fcb20836289c78,
title = "Implementation of the American Diabetes Association's Standards of Medical Care post-Medicare Part D: The case of statin utilization in the elderly with diabetes",
abstract = "Background: The American Diabetes Association's (ADA's) Standards of Medical Care in Diabetes for statin use have changed to be driven by risk status rather than low-density lipoprotein cholesterol level. Objectives: The objectives of this study were to 1) examine how statins were used by risk status in elderly diabetics for whom they are recommended by the ADA's Standards with high levels of evidence, and 2) identify potential predictors of statin non-use using data containing Medicare Part D information in understanding how to further align patient care with the ADA's Standards. Methods: This study was a pooled cross-sectional study of the Medicare Current Beneficiaries Survey from 2006 to 2010. Sampling weights were applied to generate national estimates. Weighted logistic regression was performed to identify potential predicators of statin non-use. Results: Between 2006 and 2010, 53.96{\%}, 52.14{\%}, 52.28{\%}, 57.74{\%}, and 59.81{\%} of eligible diabetics used statins, respectively. About 70{\%} of the patients with overt cardiovascular disease (CVD) took statins while only about 50{\%} of those with CVD risk factors used statins in 2010. Compared to those with overt CVD, patients with CVD risk factors were less likely to take statins (OR: 0.56; 95{\%} CI: 0.48-0.64). Other non-use predictors included: non-Hispanic Black, non-metropolitan areas, and comorbidities. Conclusions: Implementation of the ADA's statin recommendations increased over the study period. Statin use differed significantly by patients' risk status. Future ADA's Standards focusing on how to improve utilization of statins for individuals with different risk status, particularly those with CVD risk factors but without overt CVD, are warranted.",
author = "Lu, {Z. Kevin} and Minghui Li and Maxwell, {Whitney D.} and Schulz, {Richard M.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.sapharm.2015.08.001",
language = "English (US)",
volume = "12",
pages = "419--427",
journal = "Research in Social and Administrative Pharmacy",
issn = "1551-7411",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Implementation of the American Diabetes Association's Standards of Medical Care post-Medicare Part D

T2 - The case of statin utilization in the elderly with diabetes

AU - Lu, Z. Kevin

AU - Li, Minghui

AU - Maxwell, Whitney D.

AU - Schulz, Richard M.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Background: The American Diabetes Association's (ADA's) Standards of Medical Care in Diabetes for statin use have changed to be driven by risk status rather than low-density lipoprotein cholesterol level. Objectives: The objectives of this study were to 1) examine how statins were used by risk status in elderly diabetics for whom they are recommended by the ADA's Standards with high levels of evidence, and 2) identify potential predictors of statin non-use using data containing Medicare Part D information in understanding how to further align patient care with the ADA's Standards. Methods: This study was a pooled cross-sectional study of the Medicare Current Beneficiaries Survey from 2006 to 2010. Sampling weights were applied to generate national estimates. Weighted logistic regression was performed to identify potential predicators of statin non-use. Results: Between 2006 and 2010, 53.96%, 52.14%, 52.28%, 57.74%, and 59.81% of eligible diabetics used statins, respectively. About 70% of the patients with overt cardiovascular disease (CVD) took statins while only about 50% of those with CVD risk factors used statins in 2010. Compared to those with overt CVD, patients with CVD risk factors were less likely to take statins (OR: 0.56; 95% CI: 0.48-0.64). Other non-use predictors included: non-Hispanic Black, non-metropolitan areas, and comorbidities. Conclusions: Implementation of the ADA's statin recommendations increased over the study period. Statin use differed significantly by patients' risk status. Future ADA's Standards focusing on how to improve utilization of statins for individuals with different risk status, particularly those with CVD risk factors but without overt CVD, are warranted.

AB - Background: The American Diabetes Association's (ADA's) Standards of Medical Care in Diabetes for statin use have changed to be driven by risk status rather than low-density lipoprotein cholesterol level. Objectives: The objectives of this study were to 1) examine how statins were used by risk status in elderly diabetics for whom they are recommended by the ADA's Standards with high levels of evidence, and 2) identify potential predictors of statin non-use using data containing Medicare Part D information in understanding how to further align patient care with the ADA's Standards. Methods: This study was a pooled cross-sectional study of the Medicare Current Beneficiaries Survey from 2006 to 2010. Sampling weights were applied to generate national estimates. Weighted logistic regression was performed to identify potential predicators of statin non-use. Results: Between 2006 and 2010, 53.96%, 52.14%, 52.28%, 57.74%, and 59.81% of eligible diabetics used statins, respectively. About 70% of the patients with overt cardiovascular disease (CVD) took statins while only about 50% of those with CVD risk factors used statins in 2010. Compared to those with overt CVD, patients with CVD risk factors were less likely to take statins (OR: 0.56; 95% CI: 0.48-0.64). Other non-use predictors included: non-Hispanic Black, non-metropolitan areas, and comorbidities. Conclusions: Implementation of the ADA's statin recommendations increased over the study period. Statin use differed significantly by patients' risk status. Future ADA's Standards focusing on how to improve utilization of statins for individuals with different risk status, particularly those with CVD risk factors but without overt CVD, are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84941001607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941001607&partnerID=8YFLogxK

U2 - 10.1016/j.sapharm.2015.08.001

DO - 10.1016/j.sapharm.2015.08.001

M3 - Article

VL - 12

SP - 419

EP - 427

JO - Research in Social and Administrative Pharmacy

JF - Research in Social and Administrative Pharmacy

SN - 1551-7411

IS - 3

ER -